The new center of excellence provides PPD clients with a team dedicated to clinical studies in rare disease and pediatric patient populations.
Icon and the FDA are continuing development of new antibacterial treatments as part of a research project dating back to 2012.
Metrion has partnered with Assay.Works for an exchange of ion channels and high-throughput screening (HTS) services for drug discovery.
Pharmaron has acquired a majority stake in Shin Nippon Biomedical Laboratories Clinical Pharmacology Center, continuing its strategy of becoming a full service R&D service provider.
Approximately 400 clinical trials in a rare disease condition are currently registered on ClinicalTrials.gov – on Rare Disease Day 2017, Outsourcing-Pharma.com examines the numbers.